Disease · MONDO_0043797

spinal cord injury

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. spinal cord injury. Diseases, record MONDO_0043797. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043797

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: spinal cord injury; Open Targets
Open Targets ID: MONDO_0043797; Open Targets
Other names: Post-Traumatic Myelopathy, SCI, Spinal Cord Contusion, Spinal Cord Injuries, Spinal Cord Laceration, Spinal Cord Transection, Spinal Cord Trauma, Traumatic Myelopathy, injury of spinal cord; Open Targets
MeSH: D013119; MeSH
Orphanet: ORPHA:90058; Orphanet
Highest stage of its drugs: Approval, for 4 of its 60 drugs, from DailyMed and TTD; Open Targets

Drugs60

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BACLOFEN	CHEMBL701	Small molecule	Approval	DailyMed	5	1	1	Drugs and targets
PREGABALIN	CHEMBL1059	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
DANTROLENE SODIUM	CHEMBL928	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
IOPHENDYLATE	CHEMBL951	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DALFAMPRIDINE	CHEMBL284348	Small molecule	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets
MINOCYCLINE	CHEMBL1434	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
BRIVARACETAM	CHEMBL607400	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HEPATOPOIETIN-A	CHEMBL4298081		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 60

See all 60 drugs

Targets132

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	4	Androgen Receptor agonist	Phase 2/3	https://conductscience.org/library/genes/367	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
SCN10A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6332	Drugs and targets

1 to 10 of 132

See all 132 targets

Trials73

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00407745	A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury	Phase 3	220	2011-12-08	Neuralgia, Spinal Cord Injuries	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT01426555	FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)	Phase 2/3	70	2016-03-10	Osteoporosis	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01225055	Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury	Phase 2	60	2017-06-22	Spinal Cord Injury, Bone Loss, Osteoporosis	TERIPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT05639946	Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial	Phase 3	44	2026-03-18	Spinal Cord Injuries, Neuropathic Pain	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT00439140	Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder	Phase 3	41	2014-01-24	Overactive Bladder	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT00750061	Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries	Phase 2	40	2015-05-04	Spinal Cord Injury	LITHIUM CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT00755079	Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury	Phase 2/3	40	2014-07-16	Spinal Cord Injury	ALBUTEROL	Its record names the disease	ClinicalTrials.gov
NCT02323698	Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury	Phase 1/2	36	2022-08-09	Spinal Cord Injuries	CAFFEINE	Its record names the disease	ClinicalTrials.gov
NCT00266864	Testosterone Replacement Therapy in Chronic Spinal Cord Injury	Phase 2/3	31	2014-04-07	Spinal Cord Injury, Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01652040	Resistance Training and Testosterone After Spinal Cord Injury	Phase 2/3	26	2018-05-03	Spinal Cord Injury	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 73

See all 73 trials

Comparisons in its trials23

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Pregabalin vs Placebo: serious adverse events	9 of 112	10 of 107	219	NCT00407745	Trial comparisons
Pregabalin vs Placebo: Number of Participants With >=30% Reduction in Weekly Mean Pain Score From Baseline	48 of 105	33 of 105	210	NCT00407745	Trial comparisons
Pregabalin vs Placebo: Number of Participants With >=50% Reduction in Weekly Mean Pain Score From Baseline	31 of 105	16 of 105	210	NCT00407745	Trial comparisons
Pregabalin vs Placebo: Number of Participants Having Optimal Sleep Based on Medical Outcomes Study Sleep Scale (MOS-SS)	49 of 100	30 of 99	199	NCT00407745	Trial comparisons
Pregabalin vs Placebo: Number of Participants With Improvement in the Number of Attacks Based on NPSI - Number of Attacks (Item 7)	48 of 100	38 of 99	199	NCT00407745	Trial comparisons
Pregabalin vs Placebo: Number of Participants With Improved Duration of Brief Pain Attacks Based on NPSI - Duration (Item 4)	39 of 100	28 of 97	197	NCT00407745	Trial comparisons
ZA Infusion Arm vs Rowing Arm: serious adverse events	6 of 26	6 of 19	45	NCT01426555	Trial comparisons
Lithium Carbonate Tablet vs Placebo: serious adverse events	0 of 20	0 of 20	40	NCT00750061	Trial comparisons
Active Drug vs Placebo: serious adverse events	1 of 22	0 of 18	40	NCT00755079	Trial comparisons
Experimental Group vs Control Group: deaths from any cause	0 of 21	0 of 19	40	NCT05639946	Trial comparisons

1 to 10 of 23

See all 23 comparisons in its trials

Papers from its trials42

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36899099	RESULT	1	PubMed
29244816	RESULT	1	PubMed
28948164	RESULT	1	PubMed
28864949	RESULT	1	PubMed
24824524	RESULT	1	PubMed
23343764	RESULT	1	PubMed
23295632	RESULT	1	PubMed
22985379	RESULT	2	PubMed
22505632	RESULT	1	PubMed
22105463	RESULT	1	PubMed

1 to 10 of 42

See all 42 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043797

GET https://conductscience.org/api/diseases/v1/MONDO_0043797/drugs?page=2

API reference For AI assistants